Atossa Therapeutics, Quantum Leap announces initiation of I-SPY 2 trial

Atossa Therapeutics announced the initiation of a new study to evaluate Atossa’s proprietary Z-endoxifen in combination with abemaciclib, a cyclin-dependent kinase 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. “Endocrine therapy in combination with CDK 4/6 inhibition is a widely used treatment for patients with advanced-stage ER+ breast cancer and as an adjuvant therapy for node positive, hormone positive early-stage disease, found at the time of surgical resection,” said Dr. Laura Esserman, director of the University of California San Francisco Breast Care Center and founder of Quantum Leap Healthcare Collaborative. “Women with high clinical stage but less proliferative tumors are challenging to treat. Late recurrence is high regardless of either endocrine or chemotherapy. Thus, we are looking for new combined treatments, which can be used in the pre-surgery setting. We look forward to learning more about the potential of (Z)-endoxifen in combination with abemaciclib in the neoadjuvant setting in the I-SPY TRIAL.”